Framingham, MA, March 30, 2022, Nirogy Therapeutics, a biopharmaceutical company focused on oncology and Immune diseases, presented at the Cancer Immunotherapy: Decoding the cancer immunity interactome, Keystone Conference that took place from March 21-25, 2022.
A poster highlighting pre-clinical data of a small molecule dual inhibitor of lactate transporters demonstrates the potential of immune activation in the TME by differential metabolic reprogramming of various immune cells in the TME on treatment with the compound.
About Nirogy
Nirogy Therapeutics is a biotechnology company based in Boston, MA, developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
For more information, please visit www.nirogytx.com or follow us on Twitter and LinkedIn.
